A Randomized, Double-Blind, Placebo Controlled, Two-Way Cross-Over Study of Analgesic Efficacy of Bupivacaine Transdermal Therapeutic System in Patients With Post-Herpetic Neuralgia

Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Two-Way Cross-Over Study of Analgesic Efficacy of Bupivacaine Transdermal Therapeutic System in Patients With Post-Herpetic Neuralgia

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2009

At a glance

  • Drugs Bupivacaine (Primary)
  • Indications Neuropathic pain; Postherpetic neuralgia
  • Focus Therapeutic Use
  • Sponsors DURECT Corporation
  • Most Recent Events

    • 03 Feb 2009 Status changed from recruiting to completed.
    • 20 Dec 2007 Detailed results are anticipated to be presented at APS in May 2008.
    • 18 Dec 2007 Interim results reported in a DURECT Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top